Dianthus Therapeutics (DNTH) Return on Sales (2022 - 2025)
Historic Return on Sales for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to 92.5%.
- Dianthus Therapeutics' Return on Sales fell 807800.0% to 92.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.76%, marking a year-over-year decrease of 281900.0%. This contributed to the annual value of 13.55% for FY2024, which is 18100.0% up from last year.
- Per Dianthus Therapeutics' latest filing, its Return on Sales stood at 92.5% for Q3 2025, which was down 807800.0% from 163.34% recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' Return on Sales peaked at 6.68% during Q3 2022, and registered a low of 163.34% during Q2 2025.
- Moreover, its 4-year median value for Return on Sales was 15.59% (2024), whereas its average is 32.3%.
- In the last 5 years, Dianthus Therapeutics' Return on Sales skyrocketed by 42200bps in 2024 and then crashed by -1539500bps in 2025.
- Dianthus Therapeutics' Return on Sales (Quarter) stood at 8.56% in 2022, then tumbled by -188bps to 24.68% in 2023, then grew by 15bps to 21.06% in 2024, then plummeted by -339bps to 92.5% in 2025.
- Its Return on Sales was 92.5% in Q3 2025, compared to 163.34% in Q2 2025 and 25.27% in Q1 2025.